Workflow
和邦生物(603077) - 2024 Q4 - 年度业绩预告
HBCHBC(SH:603077)2025-01-17 11:00

Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between 30 million and 40 million yuan, a decrease of 124.32 million to 125.32 million yuan compared to the previous year, representing a decline of 96.88% to 97.66%[3]. - The projected net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is estimated to be between 20 million and 30 million yuan, down by 120.55 million to 121.55 million yuan year-on-year, reflecting a decrease of 97.57% to 98.38%[4]. - In 2023, the total profit was 153.60 million yuan, with a net profit attributable to shareholders of 128.32 million yuan, and a net profit after deducting non-recurring gains and losses of 123.55 million yuan[6]. Cost Management and Strategic Initiatives - The company aims to reduce costs through process innovation and precise ingredient management while accelerating the construction of its phosphate mine project to generate more profit and value[7]. Earnings Forecast Accuracy - The company does not foresee any uncertainties that could affect the accuracy of this earnings forecast[8]. - The preliminary financial data provided is subject to final auditing and may differ from the officially disclosed annual report for 2024[9].